. Author manuscript; available in PMC: 2018 Dec 1.

Published in final edited form as: J Drug Target. 2018 Jan 10;26(5-6):435–447. doi: 10.1080/1061186X.2017.1419363

Table 3.

Higher LNMC and PBMC relative to plasma for lopinavir, ritonavir and tenofovir 8 days following a single subcutaneous dose of 3-in-1 drug combination DcNPs in primates.

	LNMC/Plasma	LNMC/PBMC
Lopinavir	197.78 (93.7)	79.20 (65.9)
Ritonavir	3068.15 (111.2)	531.37 (NA)
Tenofovir	6.77 (165.3)	4.41 (198.0)

Four macaques received a single subcutaneous administration of the DcNP formulation containing lopinavir (25 mg/kg), ritonavir (6.96 mg/kg) and tenofovir (10.58 mg/kg). Data are the mean (% coefficient of variation) and are the concentration ratios at 192 h (8 days) following drug administration. NA indicates not available due to ritonavir concentrations < LLOQ in the validated LC-MS/MS assay.

LNMC: lymph node mononuclear cell; PBMC: peripheral blood mononuclear cell.